- active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
United States · Argentina · Australia - recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
United States · Argentina · Australia - recruitingPHASE2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
This study is looking at a new medicine called sparsentan for children aged 1 to 17 with certain kidney conditions like FSGS, MCD, IgAN, IgAV, and Alport Syndrome. It will check if the medicine is safe, works well, and how the body handles it over two years.
United States · Germany · Italy - active not recruitingPHASE3
Atrasentan in Patients With IgA Nephropathy
This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.
United States · Argentina · Australia - active not recruitingPHASE3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, povetacicept, for adults with a kidney condition called IgA Nephropathy. We want to see if it can help reduce protein in the urine and protect kidney function compared to a dummy medicine.
United States · Australia · Austria - recruitingPHASE2
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
This study looks at a new drug, Sparsentan, for people with kidney disease called IgA Nephropathy. It aims to see if the drug is safe and helpful in protecting the kidneys, both for newly diagnosed patients and those who have had a kidney transplant.
United Kingdom - enrolling by invitationPHASE2, PHASE3
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
This study looks at the long-term safety and effects of a medicine called sibeprenlimab for people with a kidney condition called IgA Nephropathy. It's for those who have already been part of earlier studies with this medicine.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
United States · Australia · Belgium - active not recruitingPHASE2
Atrasentan in Patients With Proteinuric Glomerular Diseases
This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.
United States · Australia · Italy